Triazolopyridazine LRRK2 kinase inhibitors

被引：24

作者：

Franzini, Maurizio ^{[1
]}

Ye, Xiaocong M. ^{[1
]}

Adler, Marc ^{[2
]}

Aubele, Danielle L. ^{[1
]}

Garofalo, Albert W. ^{[1
]}

Gauby, Shawn ^{[3
]}

Goldbach, Erich ^{[3
]}

Probst, Gary D. ^{[1
]}

Quinn, Kevin P. ^{[3
]}

Santiago, Pam ^{[3
]}

Sham, Hing L. ^{[1
]}

Tam, Danny ^{[4
]}

Anh Truong ^{[1
]}

Ren, Zhao ^{[4
]}

机构：

[1] Elan Pharmaceut, Dept Med Chem, San Francisco, CA 94080 USA

[2] Elan Pharmaceut, Dept Mol Design, San Francisco, CA 94080 USA

[3] Elan Pharmaceut, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA

[4] Elan Pharmaceut, Dept Assay Dev, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 07期

关键词：

LRRK2; Parkinson's; Inhibition; Kinase; Treatment; Discovery; Wild-type; G2019S mutant; Phosphorylation; SAR; Activity; Selectivity; Bioisostere; Hinge; HTS; Oxidative metabolism; Binding mode; Synthesis; CENTER-DOT-LICL; PARKINSONS-DISEASE; HETEROAROMATICS; AROMATICS; ZINCATION; TARGETS; BINDING;

D O I：

10.1016/j.bmcl.2013.02.043

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [1,2,4]triazolo[4,3-b]pyridazines that are potent against both wild-type and mutant LRRK2 kinase activity in biochemical assays and show an unprecedented selectivity towards the G2019S mutant. A structural rational for the observed selectivity is proposed. (C) 2013 Elsevier Ltd. All rights reserved.

引用

下载

页码：1967 / 1973

页数：7

共 50 条

[41] Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors
Greshock, Thomas J.
Sanders, John M.
Drolet, Robert E.
Rajapakse, Hemaka A.
Chang, Ronald K.
Kim, Boyoung
Rada, Vanessa L.
Tiscia, Heather E.
Su, Hua
Lai, Ming-Tain
Sur, Sylvie M.
Sanchez, Rosa I.
Bilodeau, Mark T.
Renger, John J.
Kern, Jonathan T.
McCauley, John A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (11) : 2631 - 2635
[42] Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM
Hanwen Zhu
Patricia Hixson
Wen Ma
Ji Sun
Cell Discovery, 10
[43] Capturing Differences in the Regulation of LRRK2 Dynamics and Conformational States by Small Molecule Kinase Inhibitors
Weng, Jui-Hung
Ma, Wen
Wu, Jian
Sharma, Pallavi Kaila
Silletti, Steve
McCammon, J. Andrew
Taylor, Susan
ACS CHEMICAL BIOLOGY, 2023, 18 (04) : 810 - 821
[44] Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors
Garofalo, Albert W.
Adler, Marc
Aubele, Danielle L.
Brigham, Elizabeth F.
Chian, David
Franzini, Maurizio
Goldbach, Erich
Kwong, Grace T.
Motter, Ruth
Probst, Gary D.
Quinn, Kevin P.
Ruslim, Lany
Sham, Hing L.
Tam, Danny
Tanaka, Pearl
Truong, Anh P.
Ye, Xiaocong M.
Ren, Zhao
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (07) : 1974 - 1977
[45] Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes
Mercatelli, Daniela
Bolognesi, Paolo
Frassineti, Martina
Pisano, Clarissa A.
Longo, Francesco
Shimshek, Derya R.
Morari, Michele
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (03):
[46] Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity
Yao, Chen
Johnson, William M.
Gao, Yue
Wang, Wen
Zhang, Jinwei
Deak, Maria
Alessi, Dario R.
Zhu, Xiongwei
Mieyal, John J.
Roder, Hanno
Wilson-Delfosse, Amy L.
Chen, Shu G.
HUMAN MOLECULAR GENETICS, 2013, 22 (02) : 328 - 344
[47] Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice
Korecka, Joanna A.
Thomas, Ria
Hinrich, Anthony J.
Moskites, Alyssa M.
Macbain, Zach K.
Hallett, Penelope J.
Isacson, Ole
Hastings, Michelle L.
MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 21 : 623 - 635
[48] Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration
Smith, WW
Pei, Z
Jiang, HB
Moore, DJ
Liang, YD
West, AB
Dawson, VL
Dawson, TM
Ross, CA
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (51) : 18676 - 18681
[49] Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay
Keeney, Matthew T.
Hoffman, Eric K.
Greenamyre, J. Timothy
Di Maio, Roberto
BIO-PROTOCOL, 2021, 11 (17):
[50] Screening and structural strategies for the design of selective Leucine-rich repeat kinase 2 (LRRK2) inhibitors
Chen, Ijen
David, Laurent
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248

← 1 2 3 4 5 →